0001757610-19-000003.txt : 20190813 0001757610-19-000003.hdr.sgml : 20190813 20190813152708 ACCESSION NUMBER: 0001757610-19-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190813 DATE AS OF CHANGE: 20190813 EFFECTIVENESS DATE: 20190813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zyus Life Sciences Inc. CENTRAL INDEX KEY: 0001757610 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: A9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-346449 FILM NUMBER: 191020273 BUSINESS ADDRESS: STREET 1: 407 DOWNEY RD STREET 2: SUITE 204 CITY: SASKATOON STATE: A9 ZIP: SLN4L8 BUSINESS PHONE: 306-651-7711 MAIL ADDRESS: STREET 1: 407 DOWNEY RD STREET 2: SUITE 204 CITY: SASKATOON STATE: A9 ZIP: SLN4L8 FORMER COMPANY: FORMER CONFORMED NAME: CB3 Life Sciences Ltd. DATE OF NAME CHANGE: 20181030 D 1 primary_doc.xml X0708 D LIVE 0001757610 Zyus Life Sciences Inc. 407 DOWNEY RD SUITE 204 SASKATOON A9 SASKATCHEWAN, CANADA SLN4L8 306-651-7711 SASKATCHEWAN, CANADA CB3 Life Sciences Ltd. Corporation true 2018 Brent Zettl 407 DOWNEY RD SUITE 204 SASKATOON A9 SASKATCHEWAN, CANADA S7N4L8 Executive Officer Director President and Chief Executive Officer Adam Darbellay 407 DOWNEY RD SUITE 204 SASKATOON A9 SASKATCHEWAN, CANADA S7N4L8 Executive Officer Chief Financial Officer Keith Carpenter 407 DOWNEY RD SUITE 204 SASKATOON A9 SASKATCHEWAN, CANADA S7N4L8 Executive Officer Chief Strategy & Investment Officer Michelle Gursky 407 DOWNEY RD SUITE 204 SASKATOON A9 SASKATCHEWAN, CANADA S7N4L8 Executive Officer VP Legal Affairs Larry Holbrook 407 DOWNEY RD SUITE 204 SASKATOON A9 SASKATCHEWAN, CANADA S7N4L8 Executive Officer Chief Scientific Officer Other Health Care Decline to Disclose 06b false 2019-07-31 false true true The Issuer has made this offering in connection with the acquisition of Revon Systems. Inc., pursuant to a Merger Agreement and Plan of Reorganization. 0 18101444 7783620 10317824 Additional Shares to be issued upon satisfaction of certain milestones post-merger. Original dollar amounts for offering were in CAD and were converted for this Form D filing to USD using a current conversion rate of 1 CAD = 0.76 USD. true 3 47 0 0 0 false Zyus Life Sciences Inc. Michelle Gursky Michelle Gursky VP Legal Affairs 2019-08-13